ProCE Banner Activity

MRD Status: A New Era of Individualized Medicine in Multiple Myeloma Care

Clinical Thought
The use of MRD status is making individualized treatment of multiple myeloma a reality and may be used to guide treatment decisions.

Released: November 22, 2019

Expiration: November 20, 2020

Share

Faculty

Jesús F. San-Miguel

Jesús F. San-Miguel, MD, PhD

Head, Hematology Department
Professor of Medicine
Hospital Universitario de Salamanca and Centro de Investigación del Cáncer
University of Salamanca
Salamanca, Spain

Provided by

Provided by Purdue University College of Pharmacy
ProCE Banner

Supporters

Supported by educational grants from

Celgene

Janssen administered by Scientific Affairs

Karyopharm Therapeutics

Oncopeptides

Takeda Oncology

The Binding Site

Partners

IMF 2018

ProCE Banner

Faculty Disclosure

Primary Author

Jesús F. San-Miguel, MD, PhD

Head, Hematology Department
Professor of Medicine
Hospital Universitario de Salamanca and Centro de Investigación del Cáncer
University of Salamanca
Salamanca, Spain

Jesús F. San-Miguel, MD, PhD, has disclosed that he has received consulting fees from Amgen, Bristol-Myers Squibb, Celgene, Janssen, MSD, Novartis, Roche, Sanofi, and Takeda.